Cangrelor

Drug Profile

Cangrelor

Alternative Names: AR-C 69931; AR-C69931MX; Kengreal; Kengrexal

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator AstraZeneca
  • Developer Chiesi Farmaceutici; Chiesi USA
  • Class Adenine nucleotides; Antiplatelets; Small molecules
  • Mechanism of Action Platelet ADP receptor antagonists; Purinoceptor P2Y12 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Coronary artery disease; Coronary thrombosis
  • Phase I Acute coronary syndromes

Most Recent Events

  • 03 Jan 2017 Phase-I clinical trials in Coronary thrombosis (In neonates, Prevention) in USA (IV) (NCT02765633)
  • 15 Nov 2016 Launched for Coronary thrombosis (Prevention) and Coronary artery disease in United Kingdom (IV)
  • 14 Sep 2016 Launched for Coronary thrombosis (Prevention) and Coronary artery disease in Ireland (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top